remission induction

Summary

Summary: Therapeutic act or process that initiates a response to a complete or partial remission level.

Top Publications

  1. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
  2. ncbi Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
  3. ncbi Treatment of acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology and Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    N Engl J Med 354:166-78. 2006
  4. ncbi American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Correspondence to Maarten Boers, Department of Epidemiology and Biostatistics, VU University Medical Center, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 70:404-13. 2011
  5. ncbi Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
    Javier de la Serna
    Hospital 12 de Octubre, Madrid, Spain
    Blood 111:3395-402. 2008
  6. ncbi The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
  7. pmc American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Boston University School of Medicine, Boston, Massachusetts, USA
    Arthritis Rheum 63:573-86. 2011
  8. ncbi Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
  9. pmc Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Gut 53:1617-23. 2004
  10. ncbi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010

Detail Information

Publications273 found, 100 shown here

  1. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  2. ncbi Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  3. ncbi Treatment of acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology and Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    N Engl J Med 354:166-78. 2006
  4. ncbi American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Correspondence to Maarten Boers, Department of Epidemiology and Biostatistics, VU University Medical Center, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 70:404-13. 2011
    ..This work was undertaken to develop such a definition...
  5. ncbi Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
    Javier de la Serna
    Hospital 12 de Octubre, Madrid, Spain
    Blood 111:3395-402. 2008
    ..These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL...
  6. ncbi The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
    ....
  7. pmc American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Boston University School of Medicine, Boston, Massachusetts, USA
    Arthritis Rheum 63:573-86. 2011
    ..This work was undertaken to develop such a definition...
  8. ncbi Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  9. pmc Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Gut 53:1617-23. 2004
    ..We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis...
  10. ncbi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010
    ....
  11. ncbi Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    N Engl J Med 354:1231-42. 2006
    ..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another...
  12. ncbi Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study
    Marloes Vermeer
    Arthritis Center Twente, Department of Psychology, Health and Technology, Faculty of Behavioural Sciences, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands
    Arthritis Rheum 63:2865-72. 2011
    ..The objective of this study was to develop, implement, and evaluate a treat-to-target strategy aimed at achieving remission in very early RA in daily clinical practice...
  13. ncbi Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy
    O Hotta
    Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan
    Am J Kidney Dis 38:736-43. 2001
    ..These findings indicate that interventions aimed at achieving clinical remission have provided encouraging results applicable to managing patients with IgA nephropathy...
  14. ncbi Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Tim P Hughes
    Institute of Medical and Veterinary Science, Adelaide, SA, Australia
    N Engl J Med 349:1423-32. 2003
    ..We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission...
  15. ncbi A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  16. pmc Time to achieve remission determines time to be in remission
    Lydia G Schipper
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6500 HB, The Netherlands
    Arthritis Res Ther 12:R97. 2010
    ..The aim was to study the association between time-to-remission and sustainability of remission in a cohort of early RA patients treated according to daily practice...
  17. pmc Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody
    S P Travis
    Gastroenterology Unit, Derriford Hospital, Plymouth PL6 8DH, UK
    Gut 49:725-8. 2001
    ..Infliximab could have a role for inducing remission in Behçet's syndrome...
  18. ncbi Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1360-4. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  19. ncbi Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center
    Rodrigo Cartin-Ceba
    Mayo Clinic, Rochester, Minnesota, USA
    Arthritis Rheum 64:3770-8. 2012
    ....
  20. ncbi Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Blood 116:3743-50. 2010
    ..These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319...
  21. ncbi Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
    Timo Möttönen
    Department of Medicine, Turku University Central Hospital, Turku, Finland
    Arthritis Rheum 46:894-8. 2002
    ....
  22. ncbi Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma
    Mervi Putkonen
    Department of Medicine, Turku University Central Hospital, Vaasa, Finland
    Eur J Haematol 85:416-23. 2010
    ..19 months; P = 0.003) and suggestively also for overall survival. We conclude that not only CR but also its depth is important for the long-term outcome in MM...
  23. ncbi Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
    Vikram Mathews
    Department of Haematology, Christian Medical College and Hospital, Vellore 632004, India
    Blood 107:2627-32. 2006
    ..The toxicity profile, in the majority, was mild and reversible. After remission induction, this regimen was administered on an outpatient basis...
  24. ncbi Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis
    N B Klarenbeek
    Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
    Ann Rheum Dis 70:1815-21. 2011
    ....
  25. ncbi High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
    Bruno Paiva
    Hospital Universitario de Salamanca, Spain
    Blood 119:687-91. 2012
    ..0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated...
  26. pmc Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior
    A Sah
    Department of Pharmacology and Toxicology, Institute of Pharmacy and Centre for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria
    Transl Psychiatry 2:e171. 2012
    ..Finally, rather than to higher depression-related behavior, neurogenesis seems to be linked to pathological anxiety...
  27. ncbi Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
    Marta Pratcorona
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Blood 121:2734-8. 2013
    ..In conclusion, effect of FLT3 burden is modulated by NPM1 mutation, especially in patients with a low ratio...
  28. pmc Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
    Wendy Stock
    University of Chicago, Illinois, USA
    Cancer 119:90-8. 2013
    ....
  29. ncbi The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis
    Klaus P Machold
    Medical University of Vienna, Vienna A 1090, Austria
    Ann Rheum Dis 69:495-502. 2010
    ....
  30. pmc Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
    Marinus H J van Oers
    Department of Hematology, F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2853-8. 2010
    ..Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL)...
  31. pmc Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
    Y Tanaka
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1 1 Iseigaoka, Kitakyushu 807 8555 Japan
    Ann Rheum Dis 69:1286-91. 2010
    ..Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons...
  32. ncbi Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial
    Dirk Foell
    Department of Pediatrics, University of Muenster, Albert Schweitzer Strasse 33, D 48149 Muenster, Germany
    JAMA 303:1266-73. 2010
    ..Therefore, strategies of tapering therapy and reliable parameters for detecting subclinical inflammation have now become challenging questions...
  33. ncbi Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis
    Erasmo Miele
    Department of Pediatrics, University of Naples Federico II, Naples, Italy
    Am J Gastroenterol 104:437-43. 2009
    ....
  34. ncbi The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery
    M Nannipieri
    Department of Internal Medicine, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    J Clin Endocrinol Metab 96:E1372-9. 2011
    ..Bariatric surgery can induce remission in a high proportion of severely obese patients with type 2 diabetes mellitus (T2DM)...
  35. ncbi Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    J Clin Oncol 14:2653-65. 1996
    ....
  36. ncbi The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
    Ruben Niesvizky
    Weill Cornell Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Br J Haematol 143:46-53. 2008
    ..In conclusion, bortezomib had substantial activity in relapsed myeloma patients; CR may be a surrogate marker for significant clinical benefit with bortezomib. MR appeared to be valid as a separate response category in this setting...
  37. ncbi AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
    Giuseppe Avvisati
    Unità Operativa Complessa di Ematologia e Terapia Cellulare, Università Campus Bio Medico, Roma, Italy
    Blood 117:4716-25. 2011
    ..The event-free survival estimate at 12 years was 68.9% (95% confidence interval, 66.4%-71.4%), and no differences in disease-free survival at 12 years were observed among the maintenance arms...
  38. ncbi Long-term impact of delay in assessment of patients with early arthritis
    Michael P M van der Linden
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 62:3537-46. 2010
    ..Patient characteristics associated with components of delay (by the patient, by the general practitioner [GP], and overall) were assessed...
  39. ncbi Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  40. ncbi Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation
    I Hafstrom
    The Rheumatology Unit, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Ann Rheum Dis 68:508-13. 2009
    ..To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years...
  41. ncbi Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis
    Yoko Yokoyama
    Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    Dig Dis Sci 52:2725-31. 2007
    ..Additional studies are warranted, since a low frequency of CD25(High+)CD4(+) (-) and a high frequency of CD28(-)CD4(+) (-) expressing T cells might be a predictor of clinical response to GMA...
  42. ncbi Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
    Jacob M Rowe
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
    Blood 106:3760-7. 2005
    ..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor...
  43. ncbi High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG
    E Lengfelder
    III Medizinische Universitätsklinik Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    Leukemia 23:2248-58. 2009
    ..Pretreatment WBC count > or =10 x 10(9)/l count was no relevant prognostic factor for relapse...
  44. ncbi Predictors of long-term outcome in schizophrenia
    Robin Emsley
    Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa
    Curr Opin Psychiatry 21:173-7. 2008
    ..The present review examines recent research into some of these predictors, focusing on insight, duration of untreated psychosis, cognition and early treatment response. It also addresses the need for standard outcome measures...
  45. ncbi ANCA-associated vasculitis: diagnostic and therapeutic strategy
    Shoichi Ozaki
    Division of Rheumatology and Allergy, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
    Allergol Int 56:87-96. 2007
    ..controlled trials (RCT) regarding induction and maintenance of remission of AAV indicated that the rate of remission induction by the standard regimen is approximately 90% in 6 months, that maintenance of remission can be achieved ..
  46. ncbi Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants
    Josef S Smolen
    Department of Medicine III, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
    Arthritis Rheum 63:43-52. 2011
    ..To determine the effects of tocilizumab on rheumatoid arthritis (RA) disease activity and remission assessment, using measures that do or do not comprise acute-phase reactants...
  47. ncbi The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression
    P Sobocki
    Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Int J Clin Pract 60:791-8. 2006
    ..01). We conclude that remission has a substantial health economic impact on patients treated for depression, which further strengthens the importance of aiming for full remission in the treatment of depression...
  48. ncbi Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
    Claude Preudhomme
    Laboratoire d Hematologie, Centre Hospitalier Universitaire de Lille, and INSERM Unité 837, Lille, France
    N Engl J Med 363:2511-21. 2010
    ..However, only a minority of patients treated with imatinib have a complete molecular remission...
  49. pmc Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 301:2349-61. 2009
    ..Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML...
  50. ncbi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS...
  51. pmc Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
    F Costa
    Department of Internal Medicine, Section of Gastroenterology, University of Pisa, Pisa, Italy
    Gut 54:364-8. 2005
    ..The aim of our study was to assess whether the predictive value of faecal calprotectin-a non-invasive marker of intestinal inflammation-for clinical relapse is different in ulcerative colitis (UC) and Crohn's disease (CD)...
  52. ncbi Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Peter H Wiernik
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY, USA
    J Clin Oncol 26:4952-7. 2008
    ..We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL...
  53. ncbi Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI 02906, USA
    JAMA 289:3152-60. 2003
    ..Until then, remission should continue to be based on the descriptive and experiential phenomena of symptoms and psychosocial functioning...
  54. ncbi Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
    Mats Brune
    Department of Hematology, University of Goteborg, Goteborg, Sweden
    Blood 108:88-96. 2006
    ..Side effects were typically mild to moderate. These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission...
  55. ncbi Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
    Ardeshir Ghavamzadeh
    Hematology, Oncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Kargar Ave, Tehran, Iran
    J Clin Oncol 29:2753-7. 2011
    ..Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-up results are needed...
  56. ncbi An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer
    Hagit Tulchinsky
    Proctology Unit, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Ann Surg Oncol 15:2661-7. 2008
    ....
  57. ncbi Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
    Saedis Saevarsdottir
    Rheumatology Unit, Department of Medicine, Karolinska University Hospital, 17176 Stockholm, Sweden
    Ann Rheum Dis 70:469-75. 2011
    ..To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA)...
  58. pmc Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
    Josep Maria Ribera
    Department of Hematology of the Hospitals Institut Català d Oncologia Hospital Germans Trias i Pujol, Badalona, Spain
    Haematologica 95:87-95. 2010
    ....
  59. ncbi Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial
    John B Dixon
    Centre for Obesity Research and Education, Monash University Medical School, The Alfred Hospital, Melbourne, Victoria, Australia
    JAMA 299:316-23. 2008
    ..Observational studies suggest that surgically induced loss of weight may be effective therapy for type 2 diabetes...
  60. ncbi Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission
    Wayel H Abdulahad
    University Medical Center Groningen, Groningen, The Netherlands
    Arthritis Rheum 56:2080-91. 2007
    ..The objective of this study was to test whether the frequency and/or function of Treg cells from WG patients in remission are disturbed...
  61. ncbi Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:2625-36. 2005
    ..We aimed to reevaluate or to define such criteria for the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI)...
  62. ncbi Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival
    Juan Jose Lahuerta
    Hospital Universitario de Salamanca, Salamanca, Spain
    J Clin Oncol 26:5775-82. 2008
    ..We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM...
  63. ncbi Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:2040-9. 1997
    ....
  64. pmc Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
    M F Bakker
    University Medical Center Utrecht, Department of Rheumatology and Clinical Immunology, F02 127, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Ann Rheum Dis 66:iii56-60. 2007
    ..Tight control is a treatment strategy tailored to the individual patient with RA, which aims to achieve a predefined level of low disease activity or remission within a certain period of time...
  65. pmc Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
    T Mimura
    Departments of Medicine, Surgery, and Pathology, St Mark s Hospital, London, UK
    Gut 53:108-14. 2004
    ..The aim of this study was to evaluate the effectiveness of a single daily high dose probiotic preparation (VSL#3) in maintaining antibiotic induced remission, and quality of life (QOL), for one year in such patients...
  66. ncbi HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up
    Mei Guo
    Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, Dongdajie 8, Beijing 100071, China
    J Clin Oncol 30:4084-90. 2012
    ..Whether HLA-mismatched stem-cell microtransplantation as a novel postremission therapy in these patients will improve survival and avoid graft-versus-host disease (GVHD) is still unknown...
  67. ncbi Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience
    Phil A Hart
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gut 62:1607-15. 2013
    ..There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder...
  68. pmc Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results
    Angelita Habr-Gama
    Colorectal Surgery Division, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
    Ann Surg 240:711-7; discussion 717-8. 2004
    ..Report overall long-term results of stage 0 rectal cancer following neoadjuvant chemoradiation and compare long-term results between operative and nonoperative treatment...
  69. ncbi Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
    Masayuki Towatari
    Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Blood 104:3507-12. 2004
    ..All patients except one case of early death (96%) attained complete remission (CR) after a single course of remission induction therapy...
  70. pmc The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice
    Abdoreza Davoodi-Semiromi
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
    PLoS ONE 7:e36079. 2012
    ..However, the therapeutic effects of AG490 on the development of T1D are unknown...
  71. ncbi Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
    J L Nam
    Institute Rheumatic and Musculoskeletal Medicine, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK
    Ann Rheum Dis 73:75-85. 2014
    In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction.
  72. pmc Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder
    Boadie W Dunlop
    Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 1256 Briarcliff Road NE, Building A, 3rd Floor, Atlanta, GA 30306, USA
    J Psychiatr Res 46:375-81. 2012
    ..Specific preferences for CBT or medication may reflect differing conceptualizations about depressive illness, knowledge of which may enhance treatment retention and efficacy...
  73. ncbi Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study
    Wei Jei Lee
    Department of Surgery, Min Sheng General Hospital, No 168, Chin Kuo Road, Tauoyan, Taiwan, Republic of China
    J Gastrointest Surg 16:45-51; discussion 51-2. 2012
    ..This study aims to describe recent experience with surgical treatment of T2DM in Asian centers...
  74. pmc Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis
    Gunnar Tomasson
    Boston University Vasculitis Center, Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, 72 East Concord Street, E533, Boston, MA 02118, USA
    Rheumatology (Oxford) 51:100-9. 2012
    ..The aim of this study was to explore whether either of the two distinct patterns of ANCA values during remission, a rise in ANCA or persistently positive ANCA, predicted future relapse...
  75. ncbi Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms
    Alejandro Balsa
    Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain
    Rheumatology (Oxford) 49:458-66. 2010
    ..To develop a model to predict RA outcome based on biochemical variables and single nucleotide polymorphisms (SNPs)...
  76. pmc Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mod Rheumatol 22:327-38. 2012
    ..ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice...
  77. ncbi Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Ann Surg Oncol 17:3000-7. 2010
    ....
  78. ncbi Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia
    Yuta Yoshino
    Department of Clinical Molecular Genetics, Faculty of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432 1 Horinouchi, Hachioji, Tokyo, 192 0392, Japan
    Anal Bioanal Chem 393:689-97. 2009
    ..of arsenic, the blood samples were collected at various time points from a patient with APL after remission induction therapy and during consolidation therapy...
  79. pmc Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia
    J R Roberson
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:245-50. 2009
    ..We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL...
  80. ncbi Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish
    Merete Lund Hetland
    DANBIO Registry, Copenhagen University Hospital, Department of Rheumatology, Hvidovre, Denmark
    Arthritis Rheum 62:22-32. 2010
    ....
  81. ncbi Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
    Nicola Gökbuget
    Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany
    Blood 120:1868-76. 2012
    ..Molecular response was shown to be highly predictive for outcome and therefore constitutes a relevant study end point. The studies are registered at www.clinicaltrials.gov as NCT00199056 and NCT00198991...
  82. ncbi Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study
    E Domenech
    Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Aliment Pharmacol Ther 20:1347-52. 2004
    ..Uncontrolled studies suggest that granulocyteaphaeresis might be useful in the management of active ulcerative colitis...
  83. ncbi The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation
    Hakon Reikvam
    Section for Hematology, Department of Medicine, Haukeland University Hospital and Institute of Medicine, University of Bergen
    Eur Cytokine Netw 23:140-53. 2012
    ..We shall also discuss the possibility of targeting angioregulatory cytokines as a part of the treatment strategy in leukemia...
  84. pmc Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia
    Steven M Kornblau
    Departments of Stem Cell Transplantation and Cellular Therapy and Bioinformatics and Computational Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Clin Cancer Res 16:1865-74. 2010
    ..This study evaluated the level of expression and the prognostic relevance of total and phosphorylated FOXO3A protein in AML...
  85. pmc Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis
    Paul A Monach
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Arthritis Rheum 63:3988-97. 2011
    ..To identify biomarkers that distinguish between active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and remission in a manner superior or complementary to established markers of systemic inflammation...
  86. pmc Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
    Christof Iking-Konert
    Department of Medicine III, Nephrology and Rheumatology, Universitätsklinikum UKE, 20246 Hamburg, Germany
    Ann Rheum Dis 70:1986-90. 2011
    ..6, more stringent criteria may imply the absence of disease activity. The 2011 ACR/EULAR remission criteria provide the newest and most stringent definition of remission...
  87. ncbi Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells
    K Stahnke
    University Children s Hospital, Ulm, Germany
    Leukemia 17:2130-9. 2003
    ..analyzed apoptosis induction and activation of apoptosis signaling molecules in patients receiving remission induction treatment for AML and ALL during the initial phase of leukemia cell reduction...
  88. ncbi Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
    Hagop M Kantarjian
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:549-55. 2010
    ..This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor...
  89. ncbi High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease
    Shunji Fujimori
    Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    J Gastroenterol Hepatol 22:1199-204. 2007
    ..Clinical trials of probiotic treatment for Crohn's disease (CD) have yielded conflicting results. This study assessed the clinical usefulness of combined probiotic and prebiotic therapy in the treatment of active CD...
  90. ncbi Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer
    Sang Min Yoon
    Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
    Int J Radiat Oncol Biol Phys 69:1167-72. 2007
    ..To identify pretreatment clinical parameters that could predict pathologic tumor response to preoperative chemoradiotherapy (CRT) for rectal cancer...
  91. ncbi GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors
    Roberto Latagliata
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Roma, Italy
    Br J Haematol 154:564-8. 2011
    ..However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting...
  92. ncbi Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
    Chen hua Yan
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Peoples Republic of China
    Blood 119:3256-62. 2012
    ..006, OR = 0.436, respectively). These data suggest that risk stratification-directed interventions with modified DLI in patients with standard-risk acute leukemia who are MRD(+) after transplantation may improve transplantation outcomes...
  93. pmc Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
    Viggo F Van Tendeloo
    University of Antwerp, Faculty of Medicine, Vaccine and Infectious Disease Institute Vaxinfectio and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp B 2650, Belgium
    Proc Natl Acad Sci U S A 107:13824-9. 2010
    ..These data support the further development of vaccination with WT1 mRNA-loaded dendritic cells as a postremission treatment to prevent full relapse in AML patients...
  94. ncbi Clinical differences between early and late remission in depressive patients
    Miquel Roca
    Institut Universitari d Investigacio en Ciencies de la Salut, University of Balearic Islands, Palma de Mallorca, Spain
    J Affect Disord 134:235-41. 2011
    ....
  95. pmc Treatment of inflammatory bowel disease: a review of medical therapy
    Patricia L Kozuch
    Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    World J Gastroenterol 14:354-77. 2008
    ..Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC...
  96. pmc Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria
    Shadi H Shahouri
    Arthritis and Rheumatology Clinics of Kansas and University of Kansas School of Medicine, Wichita
    Arthritis Rheum 63:3204-15. 2011
    ..To describe use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) remission criteria in clinical practice...
  97. ncbi Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery
    D E Cummings
    University of Washington School of Medicine, Seattle, WA 98195, USA
    Int J Obes (Lond) 33:S33-40. 2009
    ..Research designed to prioritize these mechanisms and identify potential additional mechanisms promises to help optimize surgical design and might also reveal novel pharmaceutical targets for diabetes treatment...
  98. ncbi Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome
    Masamitsu Yanada
    Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 78:213-9. 2007
    Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).
  99. ncbi Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
    E Di Bona
    Divisione di Ematologia, Ospedale San Bortolo, Vicenza Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Br J Haematol 108:689-95. 2000
    ....
  100. ncbi Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function
    Hayato Nagasawa
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Clin Exp Rheumatol 28:365-72. 2010
    ..We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA)...
  101. ncbi The graft-versus-leukemia effects of allogeneic cell therapy
    D L Porter
    Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Annu Rev Med 50:369-86. 1999
    ....

Research Grants73

  1. DETECTION AND THERAPY OF RESIDUAL LEUKEMIA IN CHILDREN
    Dario Campana; Fiscal Year: 2006
    ..Early detection of residual disease after remission induction may identify patients who will benefit from intensified treatment, which should then boost the proportion ..
  2. HLA-D Region in Systemic Lupus Erythematosus Pathogenesis
    Shu Man Fu; Fiscal Year: 2013
    ..The new knowledge obtained from the proposed experiments challenges the current dogma and will have an impact on our ability to treat patients with active disease and to maintain the patients'quality of life. ..
  3. Targeting renal inflammatory pathways of SLE nephritis in mouse and man
    Anne Davidson; Fiscal Year: 2013
    ..Using a unique model of remission induction of murine SLE nephritis we have identified two main physiologic pathways are associated disease onset and ..
  4. Efficacy and safety of novel CD80 IL15 IL15Ra expressing autologous AML vaccines
    KARIN L GAENSLER; Fiscal Year: 2013
    ..will elicit potent anti-leukemic responses that will improve relapse-free survival in older patients after remission induction. Mechanisms of resistance to immunotherapy include ineffective presentation of leukemia-specific or -..
  5. mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
    Alexander E Perl; Fiscal Year: 2013
    ..in validating target inhibition nor did it demonstrate an obvious advantage of the combination regimen in remission induction. To refine our approach, we performed a subsequent pilot study in which we tested a novel schedule of ..
  6. Immunologic targets in Myeloid Leukemia
    Richard J Jones; Fiscal Year: 2013
    ..settings where there is measurable evidence of an immune mediated clinical effect;in vaccine associated remission induction in 1) chronic myelogenous leukemia (CML) and 2) acute myelogenous leukemia (AML)...
  7. Genotype and phenotype of chemoresistant AML
    James C Mulloy; Fiscal Year: 2013
    ..However, the precise mechanisms whereby these molecular changes impact on remission induction, relapse and long-term survival are unknown for the most part, and within each cytogenetic risk category, ..
  8. PPAR- GAMMA LIGANDS IN ULCERATIVE COLITIS
    James Lewis; Fiscal Year: 2001
    ..It is expected that in the final 6 months of this project, the investigators will organize a multicenter randomized controlled trial of troglitazone in the treatment of mild to moderate ulcerative colitis. ..
  9. IMMUNE MECHANISMS IN HUMAN DIABETES
    MERL CHARLES; Fiscal Year: 1990
    ..Because of the current widespread research use of immunosuppressant drugs for remission induction, less toxic methods would be advantageous...
  10. Dissecting the protective and pathogenic functions of TNF alpha in SLE
    Weiqing Huang; Fiscal Year: 2009
    ..Our results should allow us to conclude whether the protective and pathogenic effects of TNFa are mediated by different receptors and may help in the design of more selective TNFa blockers for the treatment of SLE. ..
  11. Clinical Significance of Residual Myeloid Leukemia
    Dario Campana; Fiscal Year: 2010
    ..A positive MRD finding after remission induction was the most powerful predictor of treatment failure...
  12. Planing an Early RA Prevention Trial
    David Pisetsky; Fiscal Year: 2005
    ..This aim will establish the infrastructure for the trial and provide all the essential elements to allow enrollment to begin. ..
  13. Thrombospondin-1 immunoregulation and EAE
    Jose Vega; Fiscal Year: 2005
    ....
  14. Steroid Effects in Pediatric ALL Patients
    Elizabeth Soliday; Fiscal Year: 2002
    ..In the early post-diagnosis period before remission induction treatment, children's primary caregivers will complete baseline measures of their own psychological ..
  15. Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2004
    ..Flt3 internal tandem duplication, FIt3/ITD and Flt3 point mutations, FIt3/PM) may lead to lower rate of remission induction and increased rate of relapse...
  16. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2003
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  17. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  18. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
  19. Treatment of Adolescent Suicide Attempters in Dallas
    Graham Emslie; Fiscal Year: 2006
    ..This exemplary protocol stimulated the formation of a collaborative group of 8 RUPP-PI applicants. By creating the protocol, the group forged an ability to work together. ..
  20. Effects of naltrexone on active Crohn's disease
    Jill Smith; Fiscal Year: 2007
    ..Durability of response will be evaluated in a 1-month follow-up. This trial is based upon novel innovative preclinical and clinical data and may lead to a larger multi-center trial in the future. [unreadable] [unreadable] [unreadable]..
  21. Child Psychiatry Research Education Program (C-PREP)
    Graham Emslie; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. Pharmacogenetics of Asparaginase-Induced Pancreatitis
    Lewis Silverman; Fiscal Year: 2007
    ..abstract_text> ..
  23. Effects of silencing RNAs for gastrin and CCK on human pancreatic cancer
    Jill Smith; Fiscal Year: 2008
    ..These studies are the first step in bridging the results from basic science studies into the clinical realm. If shown to be effective in the animal model, we plan to proceed to treating subjects with pancreatic cancer. ..
  24. Molecular Classification and Therapy of CNS Lymphomas
    James Rubenstein; Fiscal Year: 2008
    ..We will perform gene expression profile analysis of these tumors from diagnostic specimens obtained from a frozen tumor bank to identify a set of genes, which can be used to predict outcome. ..
  25. TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTS
    Graham Emslie; Fiscal Year: 2006
    ..This site is based in Pittsburgh, which also serves as the Data Coordinating Center for the study [unreadable] [unreadable]..
  26. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007
    ..In Aim 3 we will correlate the biologic effects of 17-AAG and clinical response in patients with relapsed MCL, ALCL, and HL. [unreadable] [unreadable] [unreadable]..
  27. Geriatric Depression Outcomes: Prognostic Factors
    Warren Taylor; Fiscal Year: 2007
    ..Discussion: These findings will better describe the role of neural connectivity and striatofrontal dysfunction in geriatric depression. ..
  28. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2008
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. [unreadable] [unreadable] [unreadable]..
  29. Treatment of Advanced Pancreatic Cancer with Growth Fac*
    Jill Smith; Fiscal Year: 2005
    ..Abstract Not Provided ..
  30. GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER
    Jill Smith; Fiscal Year: 2004
    ..These studies are part of the team's long-term goal to understand the mechanisms involved in the biology of human pancreatic cancer, and contribute to the treatment and early detection of this malignancy. ..
  31. Treatment of Early Age Mania (TEAM)
    Graham Emslie; Fiscal Year: 2003
    ..D. (4) University of Texas, Dallas, PI: Graham Emslie, M.D. (5) University of Texas, Galveston, PI: Karen Dineen Wagner, M.D. and (6) Washington University, St. Louis, PI; Joan Luby, M.D. ..
  32. The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer
    Jill P Smith; Fiscal Year: 2010
    ..These studies are part of the applicant's long- term goals to understand the mechanisms controlling growth of pancreatic cancer and to diagnose patients in early stage of disease to improve long-term survival. ..
  33. Vascular Depression: Longitudinal Changes
    Warren D Taylor; Fiscal Year: 2010
    ..The proposal will provide important new data on neuroradiologic and neuropsychological factors contributing to recurrent or chronic depression in older individuals. ..
  34. Mechanism of combined 'epigenetic therapy' in myeloid malignancies
    Steven Gore; Fiscal Year: 2009
    ....
  35. Clinical Research Training Institute
    James George; Fiscal Year: 2005
    ..It is through this near one to one ratio with the trainees that ASH intends to foster and sustain interest in clinical hematologic research and thereby help stimulate the career development of future clinical researchers in hematology. ..
  36. 2006 Clinical Research Training Institute
    James George; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  37. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2002
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  38. PREVENTION OF SUICIDE IN THE ELDERLY
    George Alexopoulos; Fiscal Year: 2002
    ..Data will also be collected to document the impact of intervention on patient care, and on physician knowledge, attitudes, and satisfaction and test hypotheses derived from preliminary studies of the three IRCs. ..
  39. PREVENTION OF GERATRIC DEPRESSION
    George Alexopoulos; Fiscal Year: 2003
    ..Accordingly, we are well positioned to meet the challenges inherent in this difficult but important area of research. ..
  40. OXANDROLONE FOR THE TREATMENT OF MARROW APLASIA IN FANC*
    FRANKLIN SMITH; Fiscal Year: 2007
    ..Abstract Not Provided ..
  41. Borrelia lipoproteins with the cerebral microcirculation
    Diego Cadavid; Fiscal Year: 2007
    ..2. Investigate whether Vspl enters BMEC. 3. Determine whether Vspl crosses BMEC barriers. 4. Identify the structural features that mediate the interaction of Vspl with BMEC. [unreadable] [unreadable]..
  42. Structural Correlates of Knee Pain
    David Felson; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  43. USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
    Stephan Grupp; Fiscal Year: 2009
    ..These studies will immediately translate to the designs of follow-up studies of these agents. ..
  44. Depression: The Search for Treatment-Relevant Phenotypes
    Ellen Frank; Fiscal Year: 2009
    ..Signal detection analysis will be used to determine which combination of spectrum assessment scores and other clinical variables describe the profile of patients likely to stabilize or relapse with each of the treatments. ..
  45. Beta CELL PROGENITORS AND BONE MARROW MICROENVIRONMENT
    Dario Campana; Fiscal Year: 2004
    ..The proposed studies will further characterize the antileukemic activity of BAY 36-1677 and identify synergistically interacting compounds. ..
  46. Partners in Health and Housing Prevention Research Cent*
    C Horsburgh; Fiscal Year: 2008
    ..Abstract not provided ..
  47. Targeting FLT3 as a Novel Specific Therapy for Leukemia
    Mark Levis; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  48. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
    ..Armed with the tools to collect samples expeditiously and to measure MRD accurately, the paradigm of treating subclinical NB can then be tested in multicenter randomized studies. [unreadable] [unreadable]..
  49. Clofarabine: Cytarabine Activation for Leukemia Response
    Stefan Faderl; Fiscal Year: 2004
    ..abstract_text> ..
  50. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  51. CUTANEOUS ONCOLOGY
    Madeleine Duvic; Fiscal Year: 2004
    ..Young physicians and students who receive advanced training in the proper detection, prevention, and treatment of skin cancers will be a resource and may improve outcomes for patients of the future. ..
  52. MECHANISM OF ACTION OF CTLA41G & ANTI-CD40L IN MURINE
    Anne Davidson; Fiscal Year: 2004
    ..These findings should help determine optimal regimens for delivery of CTLA4Ig and anti-CD40L to humans and help predict their safety profiles in the autoimmune host. ..
  53. THERAPY-RELATED LEUKEMIA--CLINICAL/BIOLOGIC PREDICTORS
    Stella Davies; Fiscal Year: 2002
    ..The identification of markers of early progression to t-MDS/AML during or after therapy will also allow modification of therapy and/or the development of treatment with chemopreventive agents such as retinoids. ..
  54. Stress Reactivity & Protective Factors in Schizophrenia
    Joseph Ventura; Fiscal Year: 2003
    ..abstract_text> ..
  55. LIFESTYLE ACTIVITY FOR WEIGHT MANAGEMENT
    Thomas Wadden; Fiscal Year: 2003
    ..The predicted superiority of lifestyle activity is based on extensive pilot data and, if confirmed, should significantly improve the management of obesity and its associated health complications. ..
  56. EVOLUTION OF B PRECURSOR LEUKEMIA IN THE EU-RET MOUSE
    Stephan Grupp; Fiscal Year: 2003
    ..He will immunoprecipitate Rfp-Ret from the pro B cell populations of fetal and healthy adult E(-ret mice as well as from leukemias and compare the levels of tyrosine phophorylation of Rfp-Ret and Rfp-Ret-bound proteins. ..
  57. TREATMENT OF SOCIAL PHOBIA--MEDIATORS AND MODERATORS
    Stefan Hofmann; Fiscal Year: 2002
    ..The main hypothesis is that perceived emotional control will mediate treatment outcome and generality of effectiveness independent of the specific treatment condition. ..
  58. Cytokine Regulation of Liver Growth Hormone Signaling
    Lee Denson; Fiscal Year: 2004
    ..These findings will have implications for therapeutic strategies to ameliorate acquired GH resistance in diseases complicated by liver inflammation, including chronic cholestatic liver diseases ..
  59. HELP-SEEKING AND RECOVERY PROCESSES IN PROBLEM DRINKERS
    JALIE TUCKER; Fiscal Year: 2005
    ..Renewal of the ISA would allow Dr. Tucker to continue her current level of research involvement and development and would relieve her from reliance on short term mechanisms of support. ..
  60. Bortezomib and Idarubicin in the Treatment of AML
    DIANNA HOWARD; Fiscal Year: 2005
    ..We anticipate that with this novel treatment regimen we will observe potent anti-leukemic activity and complete clinical remissions. ..
  61. INDUCTION OF APOPTOSIS BY HIV-1 INFECTED MONOCYTIC CELLS
    Lloyd Mayer; Fiscal Year: 2007
    ..abstract_text> ..
  62. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  63. Improving AML Therapy outcome by Cholesterol Modulation
    Frederick Appelbaum; Fiscal Year: 2006
    ..Our data could have broad significance for other less experimentally tractable, statin-sensitive cancers. [unreadable] [unreadable]..
  64. Apoptosis in myelofibrosis with myeloid metaplasia
    Ruben Mesa; Fiscal Year: 2006
    ..abstract_text> ..
  65. Accurate Prediction of Acute Myeloid Leukemia Relapse
    Soheil Meshinchi; Fiscal Year: 2005
    ..With these enhancements and modifications, we believe we will be able to accurately predict relapse in more than 80% of children with AML who achieve remission. ..
  66. Sexual Dysfunction and Diabetes:Look AHEAD Sub-Study
    Stephen Schneider; Fiscal Year: 2006
    ..iii) Finally, the proposed sub-study will investigate the relationship between changes in sexual function and quality of life outcomes. ..
  67. Regulation of Bcl2 Function Via Ceramide-Activated PP2A
    Peter Ruvolo; Fiscal Year: 2006
    ..From these results, it is expected that the development of novel anticancer strategies that target mechanisms regulating Bc12 function will occur...
  68. BEHAVIOR MODIFICATION AND PHARMACOTHERAPY FOR OBESITY
    Thomas Wadden; Fiscal Year: 2002
    ..If confirmed, the above findings will have important implications for treating obesity in primary care. ..
  69. DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
    Mark Litzow; Fiscal Year: 2003
    ..The combined data will provide a comprehensive understanding of the interaction of the immune system and CML and will yield information required for the rational design of more effective clinical protocols in the future. ..
  70. MINORITY BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Peter Wiernik; Fiscal Year: 2006
    ..Efforts in screening and prevention intervention will be facilitated through the Community Outreach program and Community Council. ..
  71. TRIPTORELIN FOR OVARY PROTECTION IN CHILDHOOD LIPUS
    Hermine Brunner; Fiscal Year: 2007
    ..Abstract Not Provided ..
  72. FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE
    Mignon Loh; Fiscal Year: 2003
    ..abstract_text> ..